These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19195431)

  • 1. [Tenofovir: pharmacology and interactions].
    Azanza JR; García Quetglas E; Sádaba B; Gómez-Giu A
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():2-6. PubMed ID: 19195431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conclusions. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
    [No Abstract]   [Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
    Kearney BP; Flaherty JF; Shah J
    Clin Pharmacokinet; 2004; 43(9):595-612. PubMed ID: 15217303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir disoproxil fumarate for the treatment of HIV infection.
    Pham PA; Gallant JE
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Introduction. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():1. PubMed ID: 19195430
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current role of tenofovir in clinical medicine].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():45-54. PubMed ID: 19338072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
    Painter GR; Almond MR; Trost LC; Lampert BM; Neyts J; De Clercq E; Korba BE; Aldern KA; Beadle JR; Hostetler KY
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3505-9. PubMed ID: 17646420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are all analogue combinations equal?].
    Miralles Alvarez C
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():38-44. PubMed ID: 19195437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
    Lyseng-Williamson KA; Reynolds NA; Plosker GL
    Drugs; 2005; 65(3):413-32. PubMed ID: 15669881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
    van Leth F; Prins JM; Lange JM; Geerlings SE
    AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tenofovir as a strategy to avoid or limit adverse effects].
    Portilla J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of tenofovir in HIV and hepatitis C virus coinfection].
    Tuma P; Vispo E; Barreiro P; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():31-7. PubMed ID: 19195436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.